OBJECTIVE: To systematically review the efficacy and safety of Bufei Yishen method in the treatment of bronchial asthma in remission stage. METHODS: CNKI

Wanfang Data

VIP

PubMed and the Cochrane Library database were retrieved to collect the randomized controlled trials of Bufei Yishen method in the treatment of bronchial asthma in remission stage. The retrieval time was from the establishment of the database to Dec. 2021. Two evaluators screened the retrieved literature and extracted valid data respectively. Cochrane software was used to evaluate the literature quality

and RevMan 5.3 software was used for Meta-analysis. RESULTS: Fifteen randomized controlled trials with a total of 1 305 patients were ultimately included. Meta-analysis results showed that Bufei Yishen method was better than conventional western medicine alone in improving the clinical efficiency

traditional Chinese medicine syndrome score

lung function

interleukin（IL）-4 and IL-8 and other outcome indicators of bronchial asthma in remission stage

the differences were statistically significant（P<0.05）. The incidence of adverse drug reactions of Bufei Yishen method was similar to that of conventional western medicine

and the incidence of adverse drug reactions of Bufei Yishen method was lower with higher safety. There was no definite evidence that Bufei Yishen method was superior to conventional western medicine in improving serum NO concentration and IL-5 level. CONCLUSIONS: The results suggest that the application of Bufei Yishen method in the treatment of bronchial asthma in remission stage is superior to conventional western medicine

and has certain feasibility and application value. However

due to the low quality of clinical evidence

it is necessary to perform high-quality randomized controlled trials for further verification.